<DOC>
	<DOC>NCT02457559</DOC>
	<brief_summary>This study will determine the long-term safety, tolerability, and efficacy of tirabrutinib in adults in a prior tirabrutinib study and whose disease had not progressed on the parent study. The dosing regimen will be based on the prior dosing regimen from the parent study.</brief_summary>
	<brief_title>Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Key Currently enrolled in a prior tirabrutinib study Did not discontinue treatment with tirabrutinib for any reason other than to enroll in this study Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at enrollment in this study Any Grade 3 or 4 nonhematologic toxicity that the investigator considers related to previous tirabrutinib use must have resolved, reverted to Grade 1, or reverted to the baseline of the prior study prior to Day 1 of this study Negative serum and urine pregnancy test is required for female individuals (unless surgically sterile or greater than 2 years post menopausal) Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in the protocol. Lactating females must agree to discontinue nursing before the study drug is administered Ability and agreement to attend protocolspecified visits at the study site Able to comprehend and willing to sign the informed consent form Key Known hypersensitivity to tirabrutinib, its metabolites, or formulation excipients Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>